Galaxy银河|澳门官网·登录入口

至今,GenScript的服务及产品已被Cell, Nature, Science, PNAS等1300多家生物医药类杂志引用近万次,处于行业领先水平。NIH、哈佛、耶鲁、斯坦福、普林斯顿、杜克大学等约400家全球著名机构使用GenScript的基因合成、多肽服务、抗体服务和蛋白服务等成功地发表科研成果,再次证明GenScript 有能力帮助业内科学家Make research easy.

OVX836 a recombinant nucleoprotein vaccine inducing cellular responses and protective efficacy against multiple influenza A subtypes.

npj Vaccines. 2019-01; 
Del CampoJudith,PizzornoAndres,DjebaliSophia,BouleyJulien,HallerMarjorie,Pérez-VargasJimena,LinaBruno,BoivinGuy,HamelinMarie-Eve,NicolasFlorence,Le VertAlexandre,LeverrierYann,Rosa-CalatravaManuel,MarvelJacqueline,HillFe
Products/Services Used Details Operation
Recombinant Proteins In addition, 2 × 105 T cells were stimulated in similar conditions with 5 µg/mL of the NP366-374 (GenScript) Get A Quote

摘要

Inactivated influenza vaccines (IIVs) lack broad efficacy. Cellular immunity to a conserved internal antigen, the nucleoprotein (NP), has been correlated to protection against pandemic and seasonal influenza and thus could have the potential to broaden vaccine efficacy. We developed OVX836, a recombinant protein vaccine based on an oligomerized NP, which shows increased uptake by dendritic cells and immunogenicity compared with NP. Intramuscular immunization in mice with OVX836 induced strong NP-specific CD4+ and CD8+ T-cell systemic responses and established CD8+ tissue memory T cells in the lung parenchyma. Strikingly, OVX836 protected mice against viral challenge with three different influenza A su... More

关键词

XML 地图